Published in Mov Disord on July 01, 2005
Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm (Vienna) (2006) 1.12
Mapping the contribution of single muscles to facial movements in the rhesus macaque. Physiol Behav (2008) 1.09
Structural basis of kynurenine 3-monooxygenase inhibition. Nature (2013) 0.94
The tryptophan oxidation pathway in mosquitoes with emphasis on xanthurenic acid biosynthesis. J Insect Physiol (2006) 0.88
Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. Front Neurol (2014) 0.79
Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int J Mol Sci (2015) 0.78
Characterization of the kynurenine pathway and quinolinic Acid production in macaque macrophages. Int J Tryptophan Res (2013) 0.78
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Impaired spatial representation in CA1 after lesion of direct input from entorhinal cortex. Neuron (2008) 2.72
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet (2005) 2.28
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol (2011) 2.17
Fishermen contribute to protection of marine reserves. Nature (2010) 1.96
The structure of Mediterranean rocky reef ecosystems across environmental and human gradients, and conservation implications. PLoS One (2012) 1.83
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol (2005) 1.79
Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology (2010) 1.51
Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol (2006) 1.38
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis (2004) 1.32
Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem (2005) 1.31
The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci (2009) 1.28
Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J Neurosci (2004) 1.23
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry (2011) 1.22
Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology (2003) 1.21
Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia (2007) 1.20
Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (2010) 1.19
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol (2009) 1.18
Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull (2010) 1.18
Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets (2010) 1.16
Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem (2007) 1.15
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem (2009) 1.11
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem (2007) 1.11
Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J Pharmacol Exp Ther (2005) 1.07
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) (2011) 1.06
3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv Exp Med Biol (2003) 1.05
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci (2012) 1.04
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis (2006) 1.03
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain (2004) 1.02
Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol Cell Biol (2004) 1.01
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis (2003) 1.01
Dispersal patterns of coastal fish: implications for designing networks of marine protected areas. PLoS One (2012) 1.01
Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain. J Pharmacol Exp Ther (2011) 1.00
Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology (2011) 0.98
Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther (2007) 0.95
Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol (2012) 0.94
Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci (2013) 0.94
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging (2007) 0.93
Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem (2013) 0.93
Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord (2003) 0.92
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology (2010) 0.92
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int (2006) 0.92
Glial activation precedes seizures and hippocampal neurodegeneration in measles virus-infected mice. Epilepsia (2008) 0.92
Drosophila eye color mutants as therapeutic tools for Huntington disease. Fly (Austin) (2012) 0.91
Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J Neural Transm (Vienna) (2008) 0.91
Assessing dispersal patterns of fish propagules from an effective mediterranean marine protected area. PLoS One (2012) 0.91
Opioids and motor complications in Parkinson's disease. Trends Pharmacol Sci (2006) 0.91
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis (2004) 0.91
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res (2007) 0.90
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol (2006) 0.89
Patterns of variability in early-life traits of fishes depend on spatial scale of analysis. Biol Lett (2011) 0.89
Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain. Anal Biochem (2011) 0.89
Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophr Bull (2014) 0.88
Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol (2002) 0.88
Sequence variants in kynurenine aminotransferase II (KAT II) orthologs determine different potencies of the inhibitor S-ESBA. ChemMedChem (2008) 0.85
Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord (2004) 0.85
Curiosity to kill the KAT (kynurenine aminotransferase): structural insights into brain kynurenic acid synthesis. Curr Opin Struct Biol (2008) 0.85
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid. Neurobiol Dis (2009) 0.84
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology (2003) 0.84
L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat. Exp Neurol (2002) 0.83
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease. J Med Chem (2015) 0.83
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse (2006) 0.83
Crystal structure-based selective targeting of the pyridoxal 5'-phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement. J Med Chem (2010) 0.83
Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J Neurosci Res (2007) 0.83
NMDA-Receptor Antagonist Prevents Measles Virus-induced Neurodegeneration. Eur J Neurosci (1991) 0.83
Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology (Berl) (2014) 0.83
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging (2009) 0.82
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord (2009) 0.82
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.82
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology (2009) 0.82
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology (2013) 0.82
Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo. Eur J Neurosci (2013) 0.81
Metabotropic glutamate receptor II in the brains of Parkinsonian patients. J Neuropathol Exp Neurol (2009) 0.81
Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem (2010) 0.81
Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem (2010) 0.81
The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiol Dis (2004) 0.81
Quinolinic acid/tryptophan ratios predict neurological disease in SIV-infected macaques and remain elevated in the brain under cART. J Neurovirol (2015) 0.81